Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07838597

The Emmetropization Via Accommodation (EVA) - II Study

To determine if wearing a novel treatment during a 15-month period will enhance emmetropization in 4-month-old infants who have demonstrated poor ocular accommodation (eye focusing).

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

13 week–19 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Ohio State University College of Optometry

Columbus, Ohio, 43209, United States

About this study

Uncorrected hyperopia (farsightedness) in children can lead to significant learning and visual problems, affecting their overall well-being and academic potential. Normally, infants are born with a moderate degree of hyperopia which should decrease as undergo a normal, developmental process called emmetropization, which mostly occurs during the first 18 months of life. Sometimes, this process fails, leaving children with higher-than-normal levels of hyperopia, which significantly increases their risk of developing conditions like strabismus (crossed eyes), amblyopia (lazy eye), and early literacy and scholastic issues. Infants who are at the greatest risk of not undergoing the normal emmetropization process are those with significantly higher levels of hyperopia early in infancy and those with poor ocular accommodation. The emmetropization process is not perfectly understood in human infants but may allow a window of opportunity for early intervention to help reduce the risk of debilitating vision conditions, while the visual system is still plastic. This study seeks to determine if early intervention, specifically partial refractive correction and visual engagement exercises (meant to stimulate ocular accommodation), can help improve the accommodative response and therefore reduce hyperopia in infants at high risk of not undergoing emmetropization. By treating 4-month-old infants with poor accommodation, the study aims to facilitate emmetropization and potentially reduce the risk of long-term visual problems. The study will also explore whether hyperopic defocus or accommodative effort is the primary signal guiding emmetropization, the two major theories of human emmetropization. Positive outcomes from this research could lead to new standards of care for hyperopic infants, potentially preventing a lifetime of vision-related issues and improving early literacy and academic performance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed parental permission and HIPAA authorization and willingness to comply with study procedures.
  • Infant 13-19 weeks of age at baseline.
  • Either sex and any race or ethnicity.
  • Good general health based on parent-provided history, normal pregnancy and delivery without serious complications, and birthweight >2500 g.
  • Mean MEM accommodative lag >+1.25 D based on three measurements throughout the baseline examination.
  • Cycloplegic spherical-equivalent hyperopia ≥+3.50 D in one or both eyes.

Exclusion criteria

  • Astigmatism >2.00 D in either eye.
  • Anisometropia >1.50 D spherical equivalent.
  • Strabismus.
  • Previous difficulty with pupil dilation.
  • Cardiac, liver, asthma, or other respiratory disease.
  • Ocular disease/abnormality, prior intraocular surgery, retinal detachment, optic nerve hypoplasia, malformation of the eye, cortical visual impairment, or active ocular inflammation.
  • Hydrocephalus, Down syndrome, cerebral palsy, severe developmental delay, or seizure disorder.
  • A condition preventing spectacle wear for the study duration (e.g., plagiocephaly).

Treatment and study plan

Experimental treatment arm

Combination Product

Infants will receive spectacles that have a prescription relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D from the study protocol. An experimental non-invasive treatment will be prescribed as well. Treatment will continue until study completion at 18 months of age or until the infant reaches a spherical equivalent refractive error of +2.00D or less hyperopia. Participants will also receive a non-invasive treatment to be used at home.

Primary outcomes

  1. Ocular Accommodation measured with MEM

    Time frame: 14 months

    Change in accommodative lag (in Diopters), measured with Monocular Estimation Method (MEM).

Secondary outcomes

  1. Correlation between refractive error and ocular accommodation measured with MEM

    Time frame: 14 months

    Refractive error will be measured using retinoscopy, in Diopters (D) and ocular accommodation will be measured with MEM retinoscopy, in Diopters (D)

  2. Correlation between refractive error and ocular accommodation measured with PowerRefractor

    Time frame: 14 months

    Refractive error will be measured using retinoscopy, in Diopters (D) and ocular accommodation will be measured with the PlusOptix PowerRefractor, in Diopters (D)

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Ohio State University

Other

Registry information

Acronym: EVA-II

Important dates

Study start
2027
Primary completion
2031
Study completion
2032
First posted
Sep 24, 2026
Registry last updated
Sep 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.